SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that it received notice from the U.S. Food and Drug Administration’s Center ...
Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...
Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia ® A novel non-antibiotic approach to diarrhea treatment is important because ...
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, ...
Researchers in the U.K. analyzed vet records from over two million dogs to uncover the messy truth about canine diarrhea. Reading time 3 minutes Speaking from personal experience; fewer things in the ...
Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...
A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results